Skip to main content
. Author manuscript; available in PMC: 2019 Jun 17.
Published in final edited form as: Mol Cancer Ther. 2017 Jun 14;16(10):2083–2093. doi: 10.1158/1535-7163.MCT-17-0089

Figure 5. Aurora kinase plus BTK blockade inhibits the chronic active BCR pathway and induces apoptosis in DH/DE-DLBCL.

Figure 5.

U2932 cells were treated with 50nM alisertib, 2.0μM ibrutinib and their combination for 4 days. Western blotting shows (A) Down regulation of the MAPK and PI3K/AKT pathways but up regulation of DNA damage response, (B) Single agent alisertib induces aneuploidy due to active mTOR/AKT and ERK/MAPK pathways. But combination therapy able to overcome aneuploidy and senescence illustrated in (C).